Evidence map›Paper›PMID 22427729›Full record

ArticleCancer management and research2012

Inherited variation in pattern recognition receptors and cancer: dangerous liaisons?

Anton G Kutikhin, Arseniy E Yuzhalin

Abstract read
In one paragraph

Article in Cancer management and research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. The role of TLRs (microbe recognition receptor) in gastric cancer: An update.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  2. Article
  3. Article
  4. No genetic relationship betweenOncoTargets and therapy · 2017
    Article
  5. Review
  6. Article
  7. Review
  8. Correlation between genetic polymorphisms within IL-1B and TLR4 genes and cancer risk in a Russian population: a case-control study.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  9. Review
  10. Review
  11. Cancer: A Tale of Aberrant PRR Response.Frontiers in immunology · 2014
    Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anton G KutikhinDepartment of Epidemiology, Kemerovo State Medical Academy, Kemerovo, Russian Federation.
Arseniy E Yuzhalin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The group of pattern recognition receptors includes families of Toll-like receptors, NOD-like receptors, C-type lectin receptors, and RIG-I-like receptors. They are key sensors for a number of infectious agents, some of which are carcinogenic, and they launch an immune response against them. Inherited structural variation in genes encoding these receptors and proteins of their signaling pathways may affect their function, modulating cancer risk and features of cancer progression. Relevant malignancies, valuable gene polymorphisms, prime questions about future directions, and answers to these questions are analyzed in this review. It is possible to suggest that polymorphisms of genes encoding pattern recognition receptors and proteins of their signaling pathways may be associated with almost all cancer types, particularly with those in which carcinogenic infectious agents are responsible for the substantial share of cases (namely gastric cancer, colorectal cancer, liver cancer, cervical cancer, and nasopharyngeal carcinoma). The concept of selection of polymorphisms for further oncogenomic investigation, based on a combination of results from basic and epidemiological studies, is proposed.

Indexed as

cancerC-type lectin receptorsgene polymorphismsNOD-like receptorspattern recognition receptorsToll-like receptors

Identifiers

PMID22427729
PMCPMC3304335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.